| Assay ID | Title | Year | Journal | Article |
|---|
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347412 | qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347414 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1377747 | Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay | 2017 | European journal of medicinal chemistry, Sep-29, Volume: 138 | Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents. |
| AID715064 | Inhibition of GFP-tagged LRRK2 G2019S mutant expressed in HEK293 cells assessed as inhibition of Ser935 autophosphorylation at 0.03 to 3 uM after 90 mins by immunoblotting method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID700626 | Inhibition of LRRK2 autophosphorylation at Ser910 and Ser935 expressed in HEK293 cells at 1 uM after 90 mins by immunoblotting analysis | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID653135 | Inhibition of LRRK2 A2016T mutant expressed in HEK293 cells using nictide and ATP as substrate | 2012 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
| Characterization of TAE684 as a potent LRRK2 kinase inhibitor. |
| AID1239652 | Inhibition of LRRK2 (unknown origin) | 2015 | Journal of medicinal chemistry, Sep-10, Volume: 58, Issue:17
| Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors. |
| AID1673903 | Inhibition of GST-LRRK2 (1326 to 2527 residues) G2019S mutant (unknown origin) expressed in HEK293 cells incubated for 15 mins by cerenkov counting method | 2020 | Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
| Monomeric Targeted Protein Degraders. |
| AID1807749 | Binding affinity to recombinant human N-terminal hexaHis-tagged BRD4 expressed in Escherichia coli BL21 (DE3) cells assessed as change in melting temperature by DSF assay | 2021 | Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
| Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors. |
| AID756065 | Inhibition of wild type GST-tagged LRRK2 ((1326 to 2517 amino acids) (unknown origin) | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| The development of CNS-active LRRK2 inhibitors using property-directed optimisation. |
| AID653230 | Inhibition of LRRK2 phosphorylation at Ser910 in C57BL/6 mouse spleen at 100 mg/kg, po administered for 8 hrs followed by 2 hrs dosing | 2012 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
| Characterization of TAE684 as a potent LRRK2 kinase inhibitor. |
| AID1807755 | Binding affinity to recombinant human N-terminal hexaHis-tagged BRDT expressed in Escherichia coli BL21 (DE3) cells by qPCR assay | 2021 | Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
| Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors. |
| AID1239653 | Clearance in mouse at 1 mg/kg, iv | 2015 | Journal of medicinal chemistry, Sep-10, Volume: 58, Issue:17
| Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors. |
| AID700648 | Inhibition of LRRK2 in C57BL/6 mouse brain at 100 mg/kg, ip by ADP-acylphosphate probe-based mass spectrometry relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID1198813 | Inhibition of IL6 secretion in LPS/IL-1beta-stimulated human U87 cells compound pretreated for 30 mins before stimulation measured after 24 hrs by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation. |
| AID1807751 | Binding affinity to recombinant human N-terminal hexaHis-tagged BRD4 expressed in Escherichia coli BL21 (DE3) cells by qPCR assay | 2021 | Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
| Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors. |
| AID1807759 | Inhibition of PLK1 in HEK293T cells assessed as reduction in phosphorylation of TCTP at S46 residue at 30 to 100 nM incubated for 6 hrs by immunoblotting analysis | 2021 | Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
| Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors. |
| AID715065 | Inhibition of GFP-tagged LRRK2 G2019S mutant expressed in HEK293 cells assessed as inhibition of Ser910 autophosphorylation at 0.03 to 3 uM after 90 mins by immunoblotting method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID1807760 | Inhibition of PLK1 in human MM1.S cells assessed as reduction in c-Myc levels incubated for 6 hrs by immunoblotting analysis | 2021 | Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
| Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors. |
| AID1807754 | Binding affinity to recombinant human N-terminal hexaHis-tagged BRDT expressed in Escherichia coli BL21 (DE3) cells by MST assay | 2021 | Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
| Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors. |
| AID654031 | Inhibition of wild-type LRRK2 phosphorylation at Ser910 expressed in HEK293 cells at 0.03 to 3 uM after 90 mins by immunoblot analysis | 2012 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
| Characterization of TAE684 as a potent LRRK2 kinase inhibitor. |
| AID653205 | Inhibition of LRRK2 G2019S mutant phosphorylation at Ser935 in human lymphoblastoid cells at 0.03 to 3 uM after 90 mins by Western blot analysis | 2012 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
| Characterization of TAE684 as a potent LRRK2 kinase inhibitor. |
| AID700630 | Inhibition of LRRK2 autophosphorylation at Ser910 and Ser935 human EBV immortalized primary lymphoblastoid cells after 90 mins by immunoblotting analysis | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID1198816 | Oral bioavailability in mouse | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation. |
| AID654030 | Inhibition of wild-type LRRK2 phosphorylation at Ser935 expressed in HEK293 cells at 0.03 to 3 uM after 90 mins by immunoblot analysis | 2012 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
| Characterization of TAE684 as a potent LRRK2 kinase inhibitor. |
| AID1807758 | Inhibition of cell growth in HEK293T cells incubated for 72 hrs by CellTiter-blue reagent based assay | 2021 | Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
| Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors. |
| AID1164145 | Inhibition of recombinant LRRK2 (unknown origin) using gamma-32P-ATP assessed as LRRKtide substrate phosphorylation level at 1 uM by autoradiography | 2014 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
| Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond. |
| AID1807753 | Binding affinity to recombinant human N-terminal hexaHis-tagged BRDT expressed in Escherichia coli BL21 (DE3) cells assessed as change in melting temperature by DSF assay | 2021 | Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
| Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors. |
| AID715055 | Inhibition of LRRK2 in human lymphoblastoid cells assessed as inhibition of Ser910 autophosphorylation at 0.03 to 3 uM after 90 mins by immunoblot method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID1198815 | Inhibition of wild-type GST-tagged LRRK2 (1326 to 2527 aa)(unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation. |
| AID1198812 | Inhibition of IL6 secretion in LPS/IL-1beta-stimulated human U87 cells compound pretreated at 10 uM for 30 mins before stimulation measured after 24 hrs by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation. |
| AID756066 | Inhibition of GST-tagged LRRK2 (1326 to 2527 amino acids) G2019S mutant (unknown origin) | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| The development of CNS-active LRRK2 inhibitors using property-directed optimisation. |
| AID653189 | Inhibition of LRRK2 G2019S and A2016T mutant expressed in HEK293 cells using nictide and ATP as substrate | 2012 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
| Characterization of TAE684 as a potent LRRK2 kinase inhibitor. |
| AID1198814 | Biochemical index, ratio of IC50 for LRRK2 G2019S mutant (unknown origin) to EC50 for IL6 secretion in LPS/IL-1beta-stimulated human primary microglia | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation. |
| AID653229 | Inhibition of LRRK2 phosphorylation at Ser935 in C57BL/6 mouse kidney at 100 mg/kg, po administered for 8 hrs followed by 2 hrs dosing | 2012 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
| Characterization of TAE684 as a potent LRRK2 kinase inhibitor. |
| AID653203 | Inhibition of wild type LRRK2 phosphorylation at Ser935 in human lymphoblastoid cells at 0.03 to 3 uM after 90 mins by Western blot analysis | 2012 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
| Characterization of TAE684 as a potent LRRK2 kinase inhibitor. |
| AID1164094 | Inhibition of recombinant LRRK2 (unknown origin) using gamma-32P-ATP assessed as LRRKtide substrate phosphorylation level by autoradiography | 2014 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
| Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond. |
| AID1807756 | Binding affinity to recombinant human N-terminal hexaHis-tagged BRDT expressed in Escherichia coli BL21 (DE3) cells by ITC analysis | 2021 | Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
| Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors. |
| AID1198809 | Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation. |
| AID715066 | Inhibition of GFP-tagged LRRK2 expressed in HEK293 cells assessed as inhibition of Ser935 autophosphorylation at 0.03 to 3 uM after 90 mins by immunoblotting method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID654032 | Inhibition of LRRK2 G2019S mutant phosphorylation at Ser910 expressed in HEK293 cells at 0.03 to 3 uM after 90 mins by immunoblot analysis | 2012 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
| Characterization of TAE684 as a potent LRRK2 kinase inhibitor. |
| AID1807750 | Binding affinity to recombinant human N-terminal hexaHis-tagged BRD4 expressed in Escherichia coli BL21 (DE3) cells by MST assay | 2021 | Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
| Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors. |
| AID1198810 | Inhibition of IL6 secretion in LPS/IL-1beta-stimulated human primary microglia compound pretreated at 10 uM for 30 mins before stimulation measured after 24 hrs by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation. |
| AID654033 | Inhibition of LRRK2 G2019S mutant phosphorylation at Ser935 expressed in HEK293 cells at 0.03 to 3 uM after 90 mins by immunoblot analysis | 2012 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
| Characterization of TAE684 as a potent LRRK2 kinase inhibitor. |
| AID715067 | Inhibition of GFP-tagged LRRK2 expressed in HEK293 cells assessed as inhibition of Ser910 autophosphorylation at 0.03 to 3 uM after 90 mins by immunoblotting method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID1807763 | Inhibition of PLK1 in HEK293T cells assessed as increase in p21 levels at 0.0001 to 10 uM incubated for 6 hrs by immunoblotting analysis | 2021 | Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
| Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors. |
| AID653133 | Inhibition of wild-type LRRK2 expressed in HEK293 cells using nictide and [gamma32]ATP as substrate | 2012 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
| Characterization of TAE684 as a potent LRRK2 kinase inhibitor. |
| AID1198811 | Inhibition of IL6 secretion in LPS/IL-1beta-stimulated human primary microglia compound pretreated for 30 mins before stimulation measured after 24 hrs by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation. |
| AID653204 | Inhibition of LRRK2 G2019S mutant phosphorylation at Ser910 in human lymphoblastoid cells at 0.03 to 3 uM after 90 mins by Western blot analysis | 2012 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
| Characterization of TAE684 as a potent LRRK2 kinase inhibitor. |
| AID1164144 | Inhibition of recombinant LRRK2 (unknown origin) using gamma-32P-ATP assessed as LRRKtide substrate phosphorylation level at 10 uM by autoradiography | 2014 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
| Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond. |
| AID1807761 | Inhibition of PLK1 in human MM1.S cells assessed as increase in p21 levels incubated for 6 hrs by immunoblotting analysis | 2021 | Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
| Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors. |
| AID653228 | Inhibition of LRRK2 phosphorylation at Ser910 in C57BL/6 mouse kidney at 100 mg/kg, po administered for 8 hrs followed by 2 hrs dosing | 2012 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
| Characterization of TAE684 as a potent LRRK2 kinase inhibitor. |
| AID715054 | Inhibition of LRRK2 in human lymphoblastoid cells assessed as inhibition of Ser935 autophosphorylation at 0.03 to 3 uM after 90 mins by immunoblot method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID653134 | Inhibition of LRRK2 G2019S mutant expressed in HEK293 cells using nictide and ATP as substrate | 2012 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
| Characterization of TAE684 as a potent LRRK2 kinase inhibitor. |
| AID653202 | Inhibition of wild type LRRK2 phosphorylation at Ser910 in human lymphoblastoid cells at 0.03 to 3 uM after 90 mins by Western blot analysis | 2012 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
| Characterization of TAE684 as a potent LRRK2 kinase inhibitor. |
| AID653231 | Inhibition of LRRK2 phosphorylation at Ser935 in C57BL/6 mouse spleen at 100 mg/kg, po administered for 8 hrs followed by 2 hrs dosing | 2012 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
| Characterization of TAE684 as a potent LRRK2 kinase inhibitor. |
| AID1807752 | Binding affinity to recombinant human N-terminal hexaHis-tagged BRD4 expressed in Escherichia coli BL21 (DE3) cells by ITC analysis | 2021 | Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
| Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors. |
| AID1807757 | Inhibition of cell growth in human MM1.S cells incubated for 72 hrs by CellTiter-blue reagent based assay | 2021 | Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
| Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors. |
| AID1377746 | Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay | 2017 | European journal of medicinal chemistry, Sep-29, Volume: 138 | Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents. |
| AID700631 | Inhibition of LRRK2 G2019S mutant autophosphorylation at Ser910 and Ser935 Parkinson's patient EBV immortalized primary lymphoblastoid cells after 90 mins by immunoblotting analysis | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700627 | Inhibition of LRRK2 G2019S mutant autophosphorylation at Ser910 and Ser935 expressed in HEK293 cells at 1 uM after 90 mins by immunoblotting analysis | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1345739 | Human leucine rich repeat kinase 2 (Leucine-rich repeat kinase (LRRK) family) | 2011 | Nature chemical biology, Apr, Volume: 7, Issue:4
| Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. |
| AID1345739 | Human leucine rich repeat kinase 2 (Leucine-rich repeat kinase (LRRK) family) | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| The development of CNS-active LRRK2 inhibitors using property-directed optimisation. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |